Volver a Noticias Científicas
Investigación Científica

Detalles del Artículo

Traducción pendiente · disponible próximamente

POSTN(+) cancer-associated fibroblasts forming fortress-like barrier to mediate immunotherapy resistance in colorectal cancer.

¿Qué significa esto para los pacientes?

AI

Inicia sesión o regístrate para generar explicaciones con IA

Immune checkpoint blockade (ICB) therapy has demonstrated promising efficacy in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).

However, a substantial proportion of these patients remain resistant to treatment.

This study aims to investigate the mechanisms underlying ICB resistance in dMMR/MSI-H CRCs. We analyzed single-cell transcriptomic data from 34 CRC patients treated with ICB and integrated ten spatial transcriptomic datasets to compare the tumor microenvironment (TME) features between responders and non-responders. Our analysis identified a distinct subset of tumor-associated fibroblasts (CAFs), marked by elevated POSTN expression (POSTN+ CAFs), which was significantly enriched in non-responders. These cells encapsulate tumor cell aggregates and contribute to extensive extracellular matrix (ECM) remodeling, forming a dense, fortress-like stromal architecture at tumor periphery.

Notably, cytotoxic T cells including CXCL13+CD8+ T cells were enriched in the ECM surrounding POSTN+ CAF regions but were largely excluded from the adjacent tumor core, suggesting that POSTN+ CAFs function as a physical and biochemical barrier to T cell infiltration. Differentiation trajectory analyses revealed that POSTN+ CAFs originate from precursor CAFs (PI16+ CAFs and SFRP2+ CAFs), potentially driven by malignant cell-derived cues. Specifically, we identified GDF15 as key tumor-cell ligands that may interact with precursor CAFs to promote POSTN+ CAF differentiation.

Our findings uncover a stromal mechanism of ICB resistance in dMMR/MSI-H CRC mediated by POSTN+ CAFs and highlight novel therapeutic strategies to enhance immunotherapy efficacy.

Inicia sesión o regístrate para acceder al texto completo

Se abre en una nueva pestaña en la publicación original

Compartir y Discutir

Comentarios

¡Aún no hay comentarios. Sé el primero en comentar!

Enviar a mi oncólogo

Artículo: POSTN(+) cancer-associated fibroblasts forming fortress-like barrier to mediate immunotherapy resistance in colorectal cancer.

Autores: Zhou Y, Yu JH, Sui QQ, Liao LE, Lv RX, Liu Y, He S, Li YQ, Xu ZH, Jia ZX, Zheng MX, Mei WJ, Xiao BY, Luo CL, Bei JX, ...
Publicado: 2026-06-19
PMID: 42309220
Genes: MSI, MMR
Tratamientos: immunotherapy

Enlace: https://crcwarriors.org/article-detail.php?id=2408 | https://pubmed.ncbi.nlm.nih.gov/42309220/

¡Regístrate para usar esta función!

Crea una cuenta gratuita para enviar artículos científicos directamente a tu oncólogo y acceder a muchas más funcionalidades personalizadas.

Regístrate gratis